Screener
Monte Rosa Therapeutics, Inc. GLUE Invested capital
Discontinued — last reported Q2 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s invested capital?
- Monte Rosa Therapeutics, Inc. (GLUE) reported invested capital of $435.16M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s invested capital changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s invested capital increased by 81.5% year-over-year, from $239.78M to $435.16M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s invested capital?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s invested capital has grown at a 100.3% compound annual growth rate (CAGR), from $8.84M to $142.36M.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).
Ask your AI about Monte Rosa Therapeutics, Inc.'s invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude